$1.74 Billion is the total value of Cormorant Asset Management, LP's 72 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TPTX | New | TURNING POINT THERAPEUTICS I | $127,080,000 | – | 3,122,367 | +100.0% | 7.30% | – |
| BBIO | New | BRIDGEBIO PHARMA INC | $75,000,000 | – | 2,780,885 | +100.0% | 4.31% | – |
| STOK | New | STOKE THERAPEUTICS INC | $54,539,000 | – | 1,869,680 | +100.0% | 3.13% | – |
| QURE | New | UNIQURE NV | $46,890,000 | – | 600,000 | +100.0% | 2.69% | – |
| ASND | New | ASCENDIS PHARMA A Scall | $28,788,000 | – | 250,000 | +100.0% | 1.65% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO Lcall | $24,085,000 | – | 550,000 | +100.0% | 1.38% | – |
| MRTX | New | MIRATI THERAPEUTICS INCcall | $20,600,000 | – | 200,000 | +100.0% | 1.18% | – |
| VRTX | New | VERTEX PHARMACEUTICALS INC | $15,587,000 | – | 85,000 | +100.0% | 0.90% | – |
| NXTC | New | NEXTCURE INC | $14,980,000 | – | 1,000,000 | +100.0% | 0.86% | – |
| AKRO | New | AKERO THERAPEUTICS INC | $14,704,000 | – | 767,842 | +100.0% | 0.84% | – |
| EIGR | New | EIGER BIOPHARMACEUTICALS INC | $12,190,000 | – | 1,150,000 | +100.0% | 0.70% | – |
| HSACU | New | HEALTH SCIENCES ACQUSTN CORPunit 04/01/2024 | $11,450,000 | – | 1,080,000 | +100.0% | 0.66% | – |
| BCEL | New | ATRECA INC | $8,383,000 | – | 444,942 | +100.0% | 0.48% | – |
| QURE | New | UNIQURE NVcall | $7,815,000 | – | 100,000 | +100.0% | 0.45% | – |
| FIXX | New | HOMOLOGY MEDICINES INC | $5,871,000 | – | 300,000 | +100.0% | 0.34% | – |
| OTLK | New | OUTLOOK THERAPEUTICS INC | $32,000 | – | 15,752 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| APELLIS PHARMACEUTICALS INC | 26 | Q1 2024 | 8.6% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| ROCKET PHARMACEUTICALS, INC | 25 | Q1 2024 | 2.4% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rapport Therapeutics, Inc. | June 20, 2024 | 1,283,673 | - |
| CytomX Therapeutics, Inc. | May 13, 2024 | 5,750,000 | - |
| TScan Therapeutics, Inc. | April 29, 2024 | 2,500,000 | - |
| Immuneering Corp | April 15, 2024 | 561,128 | - |
| Ventyx Biosciences, Inc. | March 21, 2024 | 3,670,000 | - |
| Corbus Pharmaceuticals Holdings, Inc. | March 18, 2024 | 2,025,000 | - |
| 89bio, Inc.Sold out | February 14, 2024 | 0 | - |
| Aerovate Therapeutics, Inc.Sold out | February 14, 2024 | 0 | - |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2024 | 2,550,000 | - |
| Ambrx Biopharma, Inc. | February 14, 2024 | 8,725,040 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| SC 13G | 2024-06-20 |
| 4 | 2024-06-13 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.